MY136065A - Prodrugs to nmda receptor ligands - Google Patents

Prodrugs to nmda receptor ligands

Info

Publication number
MY136065A
MY136065A MYPI20013876A MYPI20013876A MY136065A MY 136065 A MY136065 A MY 136065A MY PI20013876 A MYPI20013876 A MY PI20013876A MY PI20013876 A MYPI20013876 A MY PI20013876A MY 136065 A MY136065 A MY 136065A
Authority
MY
Malaysia
Prior art keywords
prodrugs
nmda receptor
receptor ligands
compounds
lower alkyl
Prior art date
Application number
MYPI20013876A
Inventor
Alexander Alanine
Bernd Buettelmann
Holger Fischer
Marie-Paule Heitz Neidhart
Joerg Huwyler
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY136065A publication Critical patent/MY136065A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

THE INVENTION RELATES TO COMPOUNDS OF THE GENERAL FORMULA WHEREIN R IS A)-C(O) (CH2)NC(O)OH, B) WHEREIN R1 IS –N(R2)(R3) AND R2/R3 ARE INDEPENDENTLY FROM EACH OTHER HYDROGEN OR LOWER ALKYL, OR IS A CYCLIC TERTIARY AMINE, OPTIONALLY SUBSTITUTED BY LOWER ALKYL,C) –P(O)(OH)2, OR IS D) –C(O)(CH2)NNHC(O)(CH2)NN(R2)(R3); AND N IS 1, 2, 3 OR 4; AND TO PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF. THESE COMPOUNDS MAY BE USED AS PRODRUGS FOR THE PARENT COMPOUND OF FORMULA WHICH ARE USEFUL IN THE TREATMENT OF NMDA RECEPTOR-RELATED DISEASES.
MYPI20013876A 2000-08-21 2001-08-17 Prodrugs to nmda receptor ligands MY136065A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21

Publications (1)

Publication Number Publication Date
MY136065A true MY136065A (en) 2008-08-29

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20013876A MY136065A (en) 2000-08-21 2001-08-17 Prodrugs to nmda receptor ligands

Country Status (35)

Country Link
US (1) US6407235B1 (en)
EP (1) EP1313703B1 (en)
JP (1) JP4162991B2 (en)
KR (1) KR100589991B1 (en)
CN (1) CN1227230C (en)
AR (1) AR030373A1 (en)
AT (1) ATE386022T1 (en)
AU (2) AU2001285894B2 (en)
BR (1) BR0113348A (en)
CA (1) CA2419279C (en)
CY (1) CY1107937T1 (en)
CZ (1) CZ303319B6 (en)
DE (1) DE60132782T2 (en)
DK (1) DK1313703T3 (en)
EC (1) ECSP034489A (en)
EG (1) EG24293A (en)
ES (1) ES2299508T3 (en)
HR (1) HRP20030125B1 (en)
HU (1) HU229802B1 (en)
IL (1) IL154254A0 (en)
JO (1) JO2289B1 (en)
MA (1) MA26947A1 (en)
MX (1) MXPA03001311A (en)
MY (1) MY136065A (en)
NO (1) NO324941B1 (en)
NZ (1) NZ523990A (en)
PA (1) PA8525601A1 (en)
PE (1) PE20020291A1 (en)
PL (1) PL204215B1 (en)
PT (1) PT1313703E (en)
RS (1) RS51467B (en)
RU (1) RU2272027C2 (en)
SI (1) SI1313703T1 (en)
WO (1) WO2002016321A1 (en)
ZA (1) ZA200300894B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245876C2 (en) * 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Derivatives of sulfonamides and pharmaceutical composition based on thereof
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CN101374801B (en) * 2005-12-19 2014-07-02 梅特希尔基因公司 Histone deacetylase inhibitors for enhancing the activity of antifungal agents
JP2010513326A (en) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド Inhibitors of histone deacetylase and prodrugs thereof
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
KR102336426B1 (en) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda antagonist prodrugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408506A (en) * 1994-01-31 1997-08-05 Pfizer Neuroprotective compounds
DE4410822A1 (en) 1994-03-24 1995-09-28 Schering Ag New piperidine derivatives
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
CA2419279C (en) 2008-10-14
HUP0301548A3 (en) 2010-03-29
EP1313703A1 (en) 2003-05-28
JO2289B1 (en) 2005-09-12
NO324941B1 (en) 2008-01-07
KR20030022417A (en) 2003-03-15
CA2419279A1 (en) 2002-02-28
SI1313703T1 (en) 2008-06-30
RU2272027C2 (en) 2006-03-20
DE60132782T2 (en) 2009-02-05
PE20020291A1 (en) 2002-04-17
KR100589991B1 (en) 2006-06-15
EP1313703B1 (en) 2008-02-13
CZ303319B6 (en) 2012-08-01
YU13003A (en) 2006-05-25
JP4162991B2 (en) 2008-10-08
NZ523990A (en) 2004-09-24
PL361387A1 (en) 2004-10-04
CN1447793A (en) 2003-10-08
AU2001285894B2 (en) 2006-06-15
HRP20030125A2 (en) 2005-02-28
BR0113348A (en) 2003-07-08
US6407235B1 (en) 2002-06-18
ZA200300894B (en) 2004-04-30
JP2004506715A (en) 2004-03-04
CN1227230C (en) 2005-11-16
PT1313703E (en) 2008-03-25
AR030373A1 (en) 2003-08-20
MA26947A1 (en) 2004-12-20
AU8589401A (en) 2002-03-04
HK1059083A1 (en) 2004-06-18
DK1313703T3 (en) 2008-05-19
PL204215B1 (en) 2009-12-31
EG24293A (en) 2009-01-08
RS51467B (en) 2011-04-30
NO20030781D0 (en) 2003-02-19
CZ2003492A3 (en) 2004-01-14
ES2299508T3 (en) 2008-06-01
MXPA03001311A (en) 2003-06-30
WO2002016321A1 (en) 2002-02-28
PA8525601A1 (en) 2002-04-25
HUP0301548A2 (en) 2003-08-28
NO20030781L (en) 2003-02-19
DE60132782D1 (en) 2008-03-27
CY1107937T1 (en) 2013-09-04
US20020040037A1 (en) 2002-04-04
ATE386022T1 (en) 2008-03-15
HU229802B1 (en) 2014-07-28
IL154254A0 (en) 2003-09-17
HRP20030125B1 (en) 2011-07-31
ECSP034489A (en) 2003-03-31

Similar Documents

Publication Publication Date Title
DK1485359T3 (en) sodium
IL150650A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
CY1107403T1 (en) A METHOD FOR THE PREPARATION OF SUBSTANTOPRIL, THEIR analogues of these and their salts by the use of 2,5-intermediate compounds
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ATE209645T1 (en) NEW COMPOUND, METHOD FOR PRODUCTION THEREOF AND ANTITUMOR AGENTS
NZ331060A (en) Quinoxalinediones, preparation and pharmaceutical compositions thereof
GB9408185D0 (en) New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
MY133445A (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives
ATE285410T1 (en) NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF
IS6452A (en) New tetrahydropyridine, production method and pharmaceutical compositions containing them
CY1107937T1 (en) PRODUCTS IN CONNECTED NMDA CONNECTORS
HRP20031055B1 (en) NEW IMMUNOMODULATING COMPOUNDS
IS2486B (en) Aralkyl-tetrahydro-pyridine, their preparation and pharmaceutical compositions containing them
JO2433B1 (en) Process for the preparation of heterocyclic indene analogs
PL362126A1 (en) New desloratadine salts, process for their synthesis and pharmaceutical compositions thereof
EA200500032A1 (en) DERIVATIVES OF ACYLOXYPYRROLIDINE AND THEIR APPLICATION AS V1B OR V1B AND V1A RECEPTORS LIGANDS
EA200200682A1 (en) NEW COMPOUNDS OF N-BENZYLPIPERASINE, METHOD OF THEIR RECEIVING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IL150100A0 (en) Pharmaceutical compositions containing fused cyclic compounds
ATE488489T1 (en) METHOD FOR REDUCTIVE DESHALOGENATION
MXPA04002784A (en) Pharmaceutically acceptable salts of 20(s)-camptothecins.
DE69828037D1 (en) Pyrroloindole derivatives and intermediates for their preparation
GEP20074217B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing